CEO of Senhwa Biosciences, Dr. Jing-Ding Huang, said that on the one hand, Silmitasertib (CX-4945) will be used in the late stage development of the anti-infection field; on the other hand, Pidnarulex (CX-5461), a new anti-cancer drug, has already started to be used in parallel with Pfizer's PARP inhibitor. It has also entered the US National Institutes of Health (NIH) NExT Program's anti-cancer drug national team.
According to Senhwa, as the new pandemic epidemic is slowing down and countries are gradually decommissioning, various viruses such as respiratory fusion virus (RSV) and influenza are coming back in bed, triggering a global immune liability crisis. As immunity decreases after infection, the risk of death from complications is higher in populations with immune deficiencies, cancer or a history of chronic disease.
The anti-coronavirus drug Silmitasertib (CX-4945) has the potential to add value to others such as Remdesivir by inhibiting the CK2 protein kinase, an important signal mediator of viral replication, in a virus-independent manner and by acting on the host cell machinery. Senhwa has indicated that it will continue to conduct clinical studies in the field of post-epidemic anti-infection therapy to expedite the acquisition and launch of profitable drugs.
In addition to viruses, bacterial infections and bacterial resistance in the post-epidemic era are even more problematic. In a special report this year, the US CDC pointed out that the increase in the use of antibiotics in patients with new coronary artery disease has led to a significant increase in the proportion of drug-resistant bacteria, and the WHO suggested that antibiotic resistance will lead to a silent epidemic in the global medical dark ages. The WHO has also suggested that antibiotic resistance will lead to an epidemic of silence in the global medical dark ages. As a result, the company is planning to enter the late stage of development in the field of anti-infectives, and is also planning to gain a foothold in the anti-infectives field through international collaborations.
In the development of existing anti-cancer drugs, Senhwa's Pidnarulex (CX-5461) was successively selected by Pfizer and the US National Institutes of Health (NIH) for clinical trials with marketed PARP inhibitors and was added Pidnarulex has demonstrated the potential to turn cold tumors into hot tumors in preclinical studies, with important implications for the tumor microenvironment and the potential to multiply the efficacy of parallel immunosuppressive agents.
Senhwa looks forward to advancing the clinical replication of this achievement in humans under the NIH-backed NExT programme. Merck's immunotherapy drug, Keytruda, has been approved for more than a dozen cancer therapies and has global revenues of US$17 billion in 2021 and increasing every year. The market for Pidnarulex with immunotherapy is expected to improve response rates and multiply the efficacy of the treatment.
